Literature DB >> 21984191

Case-control study of blink rate in Parkinson's disease under different conditions.

Emily Fitzpatrick1, Norman Hohl, Peter Silburn, Cullen O'Gorman, Simon A Broadley.   

Abstract

Standard neurology texts list a reduced blink rate as one of the clinical features of Parkinson's disease. However, there are few clinical studies which have quantified this clinical sign. Here we present the results of a quantified study in a cohort of cases and controls using a standard protocol. Cases meeting standard criteria for a diagnosis of Parkinson's disease were studied together with age- and sex-matched controls. Baseline data included age, sex, duration of disease, Hoehn and Yahr stage, mini-mental state examination and treatment. Subjects were videoed undertaking three different tasks: being interviewed, watching a video, and reading from a book. Blink rates were calculated as a mean 'per minute' figure for each of the three tasks. A meta-analysis of previous studies of blink rate was undertaken. A total of 20 cases and 41 controls were studied. A decline in blink rate with increasing age was seen for cases but not controls. A significant reduction in blink rate was seen in cases when compared with controls for each of the test conditions. Blink rates were highest in subjects when being interviewed and were lowest whilst reading a passage in both cases and controls. No effect of disease duration, severity or treatment was observed. We have quantified the reduction in blink rate which has long been recognised as a feature of Parkinson's disease. We have identified factors which determine blink rate within individuals. We have also been able to define normal and abnormal levels for blink rate which may be of value clinically and for future research.

Entities:  

Mesh:

Year:  2011        PMID: 21984191     DOI: 10.1007/s00415-011-6261-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

1.  Eyelid movements during blinking in patients with Parkinson's disease.

Authors:  Marko Korosec; Ignac Zidar; Dik Reits; Craig Evinger; Frans Vanderwerf
Journal:  Mov Disord       Date:  2006-08       Impact factor: 10.338

2.  Blink reflex studies in patients with Parkinsonism before and during therapy.

Authors:  C A Penders; P J Delwaide
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-12       Impact factor: 10.154

3.  Analysis of eyeblink activity during discriminative tasks.

Authors:  K Fukuda
Journal:  Percept Mot Skills       Date:  1994-12

4.  The Mini-Mental State Examination.

Authors:  M F Folstein; L N Robins; J E Helzer
Journal:  Arch Gen Psychiatry       Date:  1983-07

5.  The effect of oral glucose on platelet monoamine oxidase.

Authors:  C N Karson; T P Bridge; B H Phelps; C D Wise; S G Potkin; P S Apostoles; R J Wyatt
Journal:  Biol Psychiatry       Date:  1982-09       Impact factor: 13.382

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Blink rates and disorders of movement.

Authors:  C N Karson; R S Burns; P A LeWitt; N L Foster; R P Newman
Journal:  Neurology       Date:  1984-05       Impact factor: 9.910

8.  Ophthalmologic features of Parkinson's disease.

Authors:  V Biousse; B C Skibell; R L Watts; D N Loupe; C Drews-Botsch; N J Newman
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

9.  Ocular manifestations in progressive supranuclear palsy.

Authors:  D D Pfaffenbach; D D Layton; T P Kearns
Journal:  Am J Ophthalmol       Date:  1972-12       Impact factor: 5.258

10.  Analysis of blink rate patterns in normal subjects.

Authors:  A R Bentivoglio; S B Bressman; E Cassetta; D Carretta; P Tonali; A Albanese
Journal:  Mov Disord       Date:  1997-11       Impact factor: 10.338

View more
  8 in total

1.  Evaluation of corneal parameters in patients with Parkinson's disease.

Authors:  Seden Demirci; Alime Gunes; Hasan Rifat Koyuncuoglu; Levent Tok; Ozlem Tok
Journal:  Neurol Sci       Date:  2016-04-07       Impact factor: 3.307

2.  Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy.

Authors:  Abbe H Crawford; John C W Hildyard; Sophie A M Rushing; Dominic J Wells; Maria Diez-Leon; Richard J Piercy
Journal:  Dis Model Mech       Date:  2022-03-02       Impact factor: 5.758

3.  Meibum Lipid Composition and Conformation in Parkinsonism.

Authors:  Solomon Blinchevsky; Aparna Ramasubramanian; Douglas Borchman; Shanzeh Sayied; Krithika Venkatasubramanian
Journal:  EC Ophthalmol       Date:  2021-03-31

4.  Preliminary effects of prefrontal tDCS on dopamine-mediated behavior and psychophysiology.

Authors:  Michael J Imburgio; Hannah K Ballard; Astin C Cornwall; Darrell A Worthy; Jessica A Bernard; Joseph M Orr
Journal:  Behav Brain Res       Date:  2021-01-10       Impact factor: 3.332

Review 5.  The motor prodromes of parkinson's disease: from bedside observation to large-scale application.

Authors:  C Simonet; A Schrag; A J Lees; A J Noyce
Journal:  J Neurol       Date:  2019-12-04       Impact factor: 4.849

6.  Spontaneous Eye Blink Rate (EBR) Is Uncorrelated with Dopamine D2 Receptor Availability and Unmodulated by Dopamine Agonism in Healthy Adults.

Authors:  Linh C Dang; Gregory R Samanez-Larkin; Jaime J Castrellon; Scott F Perkins; Ronald L Cowan; Paul A Newhouse; David H Zald
Journal:  eNeuro       Date:  2017-09-18

Review 7.  How to spot ocular abnormalities in progressive supranuclear palsy? A practical review.

Authors:  Onanong Phokaewvarangkul; Roongroj Bhidayasiri
Journal:  Transl Neurodegener       Date:  2019-07-10       Impact factor: 8.014

8.  Blink rate is associated with drug-induced parkinsonism in patients with severe mental illness, but does not meet requirements to serve as a clinical test: the Curacao extrapyramidal syndromes study XIII.

Authors:  Charlotte L Mentzel; P Roberto Bakker; Jim van Os; Marjan Drukker; Glenn E Matroos; Marina A J Tijssen; Peter N van Harten
Journal:  J Negat Results Biomed       Date:  2017-08-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.